REGENXBIO Inc.
For the period ended Mar 31, 2026. Filed May 14, 2026.
View on SEC.govAbout this filing
A company's report for each of its first three quarters. The financial statements are not audited. It shows how the business has moved since the last annual report, and what management says changed.
Mar 31, 2026 · Filed May 14, 2026
Extracted filing text, with the paragraph anchors used by the comparison.
See the whole filing, with its images and exhibitsContents
Item 6. Exhibits
| Incorporated by Reference | |||||
|---|---|---|---|---|---|
| ExhibitNumber | Description | Form | ExhibitNumber | Filing Date | Filed orFurnishedHerewith |
| 3.1 | Restated Certificate of Incorporation | 8-K | 3.1 | 6/7/21 | |
| 3.2 | Amended and Restated Bylaws | 10-K | 3.2 | 3/5/26 | |
| 10.1† | Settlement and Release Agreement dated March 18, 2026 between the Registrant and GlaxoSmithKline LLC | X | |||
| 10.2† | License Agreement dated August 16, 2018 between the Registrant and Emory University | X | |||
| 31.1 | Certification of the Chief Executive Officer as required by Section 302 of the Sarbanes-Oxley Act of 2002 | X | |||
| 31.2 | Certification of the Chief Financial Officer as required by Section 302 of the Sarbanes-Oxley Act of 2002 | X | |||
| 32.1 | Certifications of the Chief Executive Officer and Chief Financial Officer as required by 18 U.S.C. 1350 | X | |||
| 101 | The following materials from the Company’s Quarterly Report on Form 10-Q for the fiscal quarter ended March 31, 2026 formatted in Inline XBRL (eXtensible Business Reporting Language): (i) Consolidated Balance Sheets(ii) Consolidated Statements of Operations and Comprehensive Income (Loss)(iii) Consolidated Statements of Stockholders’ Equity(iv) Consolidated Statements of Cash Flows(v) Notes to Consolidated Financial Statements | X | |||
| 104 | The cover page from the Company’s Quarterly Report on Form 10-Q for the fiscal quarter ended March 31, 2026 formatted in Inline XBRL (included in Exhibit 101) | ||||
† Portions of this exhibit have been omitted.
The certification attached as Exhibit 32.1 that accompanies this Quarterly Report on Form 10-Q is not deemed filed with the SEC and is not to be incorporated by reference into any filing of REGENXBIO Inc. under the Securities Act or the Exchange Act, whether made before or after the date of this Quarterly Report on Form 10-Q, irrespective of any general incorporation language contained in such filing.
The text of this filing, as the company filed it with the SEC, without its images or exhibits. This is not investment advice.